G1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

G1 Therapeutics

08/08/2024 14:31

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 10 cents​​ per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of 14 cents.  The mean expectation of six analysts for the
quarter was for a loss of 16 cents per share. Wall Street
expected results to range from -18 cents to -15 cents per share.
    * Revenue fell 61% to $16.55 million from a year ago;
analysts
expected $16.36 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 10 cents​.
    * The company reported a quarterly loss of $5.47 million.
    * G1 Therapeutics Inc shares had risen by 209.6% this
quarter and
gained 131.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for G1 Therapeutics
Inc is $6.00 
This summary was machine generated from LSEG data August 8 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.16          -0.10          Beat
 Mar. 31 2024      -0.21          -0.20          Beat
 Dec. 31 2023      -0.28          -0.21          Beat
 Sep. 30 2023      -0.33          -0.35          Missed